Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.60 |
| ▸ | KDR | P35968 | 9/20 | 0.60 |
| ▸ | BRAF | P15056 | 6/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3947811 | 0.97 | KDR (0.59) | EGFRKDRBRAFCA2CA9 | |
| SCHEMBL13881876 | 0.93 | EGFR (0.51) | EGFRKDRBRAFCA2CA9 | |
| SCHEMBL3948976 | 0.92 | BRAF (0.60) | EGFRKDRBRAFCA2CA9 | |
| SCHEMBL3945598 | 0.88 | KDR (0.72) | EGFRKDRBRAFFLT1FLT4 | |
| SCHEMBL3947634 | 0.88 | KDR (0.72) | EGFRKDRBRAFFLT1FLT4 | |
| SCHEMBL3953829 | 0.88 | KDR (0.71) | EGFRKDRBRAFFLT1FLT4 | |
| SCHEMBL3954138 | 0.88 | KDR (0.71) | EGFRKDRBRAFFLT1FLT4 | |
| SCHEMBL3946977 | 0.87 | EGFR (0.66) | EGFRKDRBRAFRAF1FLT1 | |
| SCHEMBL3945278 | 0.87 | EGFR (0.66) | EGFRKDRBRAFRAF1FLT1 | |
| SCHEMBL3945583 | 0.87 | KDR (0.81) | EGFRKDRBRAFRAF1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1885719-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006066795-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | EGFR 437/4885KDR 1657/4885BRAF 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.